Probi Overview
- Year Founded
-
1991
- Status
-
Private
- Employees
-
157
- Latest Deal Type
-
2ndary - Open
- Latest Deal Amount
-
$89.5M
Probi General Information
Description
Probi AB is engaged in probiotic research and development, manufacturing and sales of effective and well-documented probiotics. Its research relates to living microorganisms with scientific health benefits. The main fields of research are gut health, immune system and nutrient absorption, iron absorption, bone health and stress and recovery. It operates in Consumer Healthcare (CHC) and Functional Food (FF). The company operates in United States, Americas, excluding the United States , Sweden, EMEA, excluding Sweden, and APAC. The company's business is divided into three operating segments. These segments are based on a geographical division and consist of the regions Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia and the Pacific).
Contact Information
Website
www.probi.seCorporate Office
- Ideongatan 1A
- 223 70 Lund
- Sweden
Corporate Office
- Ideongatan 1A
- 223 70 Lund
- Sweden
Probi Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Secondary Transaction - Open Market | 16-Jan-2025 | $89.5M | Completed | Profitable | ||
| 7. Merger/Acquisition | 01-Jan-2016 | Completed | Profitable | |||
| 6. Merger/Acquisition | 11-Feb-2014 | Cancelled | Profitable | |||
| 5. Secondary Transaction - Private | 10-Jan-2014 | Completed | Profitable | |||
| 4. Secondary Transaction - Open Market | 01-Aug-2012 | Completed | Profitable | |||
| 3. Secondary Transaction - Private | 07-Sep-2011 | Completed | Profitable | |||
| 2. IPO | 02-Dec-2004 | $8.48M | $8.48M | Completed | Profitable | |
| 1. Later Stage VC | 30-Jun-2000 | Completed | Generating Revenue |
Probi Comparisons
Industry
Financing
Details
Probi Competitors (1)
One of Probi’s competitors is AstraZeneca, a Formerly PE-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AstraZeneca | Formerly PE-Backed | Cambridge, United Kingdom |
Probi Patents
Probi Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026017258-A1 | Lacticaseibacillus compositions and uses thereof | Pending | 18-Jul-2024 | ||
| WO-2026017905-A1 | Lacticaseibacillus compositions and uses thereof | Pending | 18-Jul-2024 | ||
| AU-2020294892-A1 | Lactobacillus compositions and uses thereof | Pending | 18-Jun-2019 | ||
| CA-3139619-A1 | Lactobacillus compositions and uses thereof | Pending | 18-Jun-2019 | ||
| EP-3986433-A1 | Lactobacillus compositions and uses thereof | Pending | 18-Jun-2019 | A61K35/747 |
Probi Signals
Probi Investments & Acquisitions (5)
Probi’s most recent deal was a PIPE with BLIS Technologies for . The deal was made on 06-Jul-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| BLIS Technologies | 06-Jul-2021 | PIPE | Biotechnology | ||
| Vital Nutrients | 20-Oct-2020 | Corporate | Other Consumer Non-Durables | ||
| VivaPro | 24-Mar-2020 | Joint Venture | Other Consumer Non-Durables | ||
| Nutraceutix | 03-Oct-2016 | Merger/Acquisition | Pharmaceuticals | ||
| Probac (IP Rights for Two Thermostable Strains in Lund, Sweden) | 11-Mar-2016 | Corporate Asset Purchase | Buildings and Property |
Probi ESG
Risk Overview
Risk Rating
Updated October, 31, 2024
28.08 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,999
Rank
Percentile
Pharmaceuticals
Industry
of 952
Rank
Percentile
Biotechnology
Subindustry
of 444
Rank
Percentile
Probi Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Nutraceutix | Redmond, WA | 1984 |
Probi FAQs
-
When was Probi founded?
Probi was founded in 1991.
-
Where is Probi headquartered?
Probi is headquartered in Lund, Sweden.
-
What is the size of Probi?
Probi has 157 total employees.
-
What industry is Probi in?
Probi’s primary industry is Other Consumer Non-Durables.
-
Is Probi a private or public company?
Probi is a Private company.
-
What is Probi’s current revenue?
The current revenue for Probi is .
-
How much funding has Probi raised over time?
Probi has raised $8.48M.
-
Who are Probi’s competitors?
AstraZeneca is a competitor of Probi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process